Managed FinOps for a biotech scale-up

The client is a UK genomics biotech scale-up whose compute-heavy research pipelines drove a fast-rising cloud bill. For a scale-up, every euro spent on undifferentiated infrastructure is a euro not spent on science.

Spend was growing faster than funding and could not be attributed to specific research programmes, so there was no way to judge what was worth it.

Genomics compute costs were growing faster than funding, threatening runway for a scale-up that needed every euro for science. Cost growth was becoming a strategic risk, not just an operational one.

No one could attribute spend to a specific programme, so there was no way to know what was worth it. Without visibility, cost control was impossible to do intelligently.

Any cost control had to avoid slowing the research pipelines the business exists to run. Savings could not come at the expense of scientific throughput.

We instrumented cost down to the research programme, so spend finally had an owner and a purpose attached. Attribution is the prerequisite for every other FinOps decision.

With that visibility we right-sized resources and committed capacity where usage was predictable, capturing savings without touching performance. The savings came from waste and mispricing, not from throttling research.

Guardrails went into the research workflow so waste is prevented rather than discovered on the next bill, and throughout we protected pipeline throughput as the hard constraint. Scientists kept their speed while the bill came down.